FDA advisers find no major Halcion danger

被引：2

|

作者：

Ault, A

机构：

来源：

LANCET | 1997年 / 350卷 / 9093期

关键词：

D O I：

10.1016/S0140-6736(05)63599-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1760 / 1760

页数：1

相关论文

共 50 条

[1] FDA ON UPJOHN AND HALCION
MCCARTHY, M
[J]. LANCET, 1994, 343 (8907): : 1216 - 1217
[2] Drug for low sexual desire carries significant harms, FDA advisers find
Moynihan, Ray
[J]. BRITISH MEDICAL JOURNAL, 2010, 341
[3] Upjohn and FDA criticised over Halcion
Barnett, AA
[J]. LANCET, 1996, 347 (9015): : 1616 - 1616
[4] FDA ADVISERS OKAY NEXSTARS DAUNOXOME
FOX, JL
[J]. BIO-TECHNOLOGY, 1995, 13 (07): : 635 - 636
[5] FDA ADVISERS SPURN TOUGH DARVON CONTROLS
SMITH, RJ
[J]. SCIENCE, 1979, 204 (4394) : 712 - 713
[6] FDA advisers vote against nonprescription lovastatin
Traynor, K
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (05) : 455 - +
[7] FDA ADVISERS CLEAR VIVUS OBESITY DRUG
不详
[J]. CHEMICAL & ENGINEERING NEWS, 2012, 90 (09) : 19 - 19
[8] FDA advisers wary of expanding quetiapine use
Traynor, Kate
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (10) : 880 - +
[9] FDA advisers recommend approval of biosimilar filgrastim
Traynor, Kate
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (04) : 262 - +
[10] FDA advisers again reject nonprescription lovastatin
Traynor, Kate
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (02) : 101 - +

← 1 2 3 4 5 →